HER2 OVEREXPRESSION

Clinical trials for HER2 OVEREXPRESSION explained in plain language.

Never miss a new study

Get alerted when new HER2 OVEREXPRESSION trials appear

Sign up with your email to follow new studies for HER2 OVEREXPRESSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New cancer drug trial targets specific genetic flaws

Disease control Recruiting now

This early-stage study is testing a new oral drug called CGT4255 in adults with advanced solid tumors that have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to find a safe dose and see if the drug can shrink tumors, including those that …

Matched conditions: HER2 OVEREXPRESSION

Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

HER2 OVEREXPRESSION

Get alerted when new HER2 OVEREXPRESSION trials appear

New cancer drug trial targets specific genetic flaws